NCCN

NCCN Foundation Announces Recipients for 2024 Young Investigator Awards Honoring Future Leaders of Cancer Research

Retrieved on: 
Montag, April 15, 2024
YIA, Genetics, NCCN, Pfizer, Daiichi Sankyo, Abstract, Merck & Co., National Comprehensive Cancer Network, MD, Conference, Research, Prostate cancer, Kidney cancer, Merck, Cervical cancer

PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced five winners for the 2024 NCCN Foundation Young Investigator Awards (YIA). These annual awards honor some of the most promising new oncology researchers from across NCCN's Member Institutions. Investigator selection and project oversight is organized through the NCCN Oncology Research Program (ORP). Funding of up to $150,000 over two years per awardee will be provided by the NCCN Foundation.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced five winners for the 2024 NCCN Foundation Young Investigator Awards (YIA).
  • Investigator selection and project oversight is organized through the NCCN Oncology Research Program (ORP).
  • Funding of up to $150,000 over two years per awardee will be provided by the NCCN Foundation .
  • The 2024 NCCN Foundation Young Investigator Award recipients are:
    A Phase 2 Trial of IO102/IO103 and Nivolumab-Relatlimab Fixed-dose Combination in Previously Untreated, Unresectable Melanoma
    "The YIA program is a cornerstone of our work to advance cancer care," said Patrick Delaney, Executive Director, NCCN Foundation.

NCCN 2024 Annual Conference Shares Cancer Care Updates for Practical, Immediate Use in Practice

Retrieved on: 
Donnerstag, April 11, 2024
Maker, Congress, University, Cancer, NCCN, Risk, Policy, National Comprehensive Cancer Network, Hereditary nonpolyposis colorectal cancer, MD, Conference, BCPS, Research, University of Utah Hospital, Genetic testing, Patient, Doctor of Pharmacy, Physician, Caregiver, MBA, MHA, Pharmacist, Nursing

PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7. The yearly meeting includes opportunities for care providers to interact with world-renowned specialists on the latest evidence-based expert consensus recommendations for delivering high quality, patient-centered cancer care. Sessions focused on practical applications for improving care at every level, including clinical and administrative tracks, patient perspectives, and pressing policy issues.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7.
  • It includes both the clinical and administrative aspects of cancer care delivery; practical things to apply immediately.
  • "Clinical practice guidelines and continuing education events such as NCCN's Annual Conference democratize care and disseminate knowledge.
  • Other sessions delved into the latest updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for numerous cancer types, including:

Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference

Retrieved on: 
Mittwoch, März 27, 2024
Feasibility, Conference, Safety, Central nervous system, CNS, NCCN, PSTV, National Comprehensive Cancer Network, Therapy, Cancer, Poster, Plus Therapeutics, Pharmaceutical industry

AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida.

Key Points: 
  • AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida.
  • Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update of Initial Safety and Feasibility

Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network

Retrieved on: 
Montag, April 8, 2024
Clinical research, Stanford Cancer Institute, Hematology, Oncology, Associate, Caregiver, Colorectal cancer, Education, Chairperson, Patient, FACP, Research, NCCN, University, Cancer, Glomus tumor, Fox Chase Cancer Center, Leukemia, MBA, FRCP, MPH, Drug development, Health, Management

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
  • He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
  • "As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization's mission."
  • "I am very honored to serve as the Vice-Chair of the NCCN Board of Directors," said Dr. Lieu.

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, März 21, 2024
AYA, Research, Remuneration, Civil service commission, Administration, Conference, Net, Growth, Young adult, Fennec, FENC, Patient, Into, G&A, NCCN, Adolescence, Marketing, MHRA, TSX, European Commission, FDA, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update.

Key Points: 
  • ET ~
    RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update.
  • PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
  • Achieved PEDMARK net product revenue of approximately $9 million and $21 million for the fourth quarter and full year 2023, respectively.
  • Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023
    Net Sales – Net product sales of $21.3 million in fiscal 2023 compared to $1.5 million in 2022.

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Retrieved on: 
Mittwoch, März 13, 2024
HCC, Research, PIN, Conference call, Congress, Relative value unit, Conference, Head, Exercise, NSCLC, Risk, Patient, CHRS, Otorhinolaryngology, Biomarker, Sale, Acquisition, NCCN, NPC, Ophthalmology, IL-27, IND, Bevacizumab, OPSCC, Investigational New Drug, Investment, ESMO, GAAP, Workforce, Medicare, FDA, COGS, Total, Development, Pharmaceutical industry

UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.

Key Points: 
  • UDENYCA net product sales increased 10% in the fourth quarter 2023 to $36.2 million compared to $33.0 million in the third quarter.
  • Since commercial launch in May 2023, more than 727 accounts have ordered the Autoinjector presentation.
  • “Throughout 2023, Coherus demonstrated significant progress in transforming the Company’s business model and product portfolio for long-term sustainable growth,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer.
  • Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million.

Novotech Publishes Precision Oncology Landscape Whitepaper Identifying Current Trends and Opportunities in Targeted Therapies

Retrieved on: 
Mittwoch, März 13, 2024
Diagnosis, Checkmate, Prevalence, Patient, World Games, SWOT, Biomarker, Research, NCCN, Cancer, EMA, Contract research organization, National Comprehensive Cancer Network, Protein, Medicine, Clinical trial, Drug development, Therapy, Precision, FDA, Pharmaceutical industry

Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.

Key Points: 
  • Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.
  • The Precision Oncology - Global Clinical Trial Landscape whitepaper is designed for researchers, clinicians, pharmaceutical, biopharma and biotech firms.
  • It presents a thorough analysis of healthcare, technology, macroeconomic, regulatory trends, SWOT analysis, funding, and innovative research developments in precision oncology.
  • The report provides a detailed review of the current precision oncology landscape including standout trials, important trends around FDA approvals, funding initiatives, and ongoing insights impacting research and development.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

Retrieved on: 
Dienstag, März 12, 2024
Diagnosis, Growth, Prostate cancer, Patient, Research, NCCN, Death, National Comprehensive Cancer Network, Insurance, Medicare

IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel.

Key Points: 
  • IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel.
  • With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing cancer, disease progression, and response to prostate cancer therapies.
  • Germline testing of prostate cancer patients is recommended in the National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans, for eligible patients.
  • Decades of research indicate that prostate cancer has a strong genetic component with implications to ancestry.

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Retrieved on: 
Samstag, April 6, 2024
Research, Women, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Orbis, Urinary tract infection, Cardiac arrest, Stomatitis, Patient, Stroke, Lung cancer, University, Acute kidney injury, Neoplasm, Therapy, Anemia, Vomiting, Pleural effusion, Cellulitis, Shock (mechanics), Periodic breathing, Colorectal cancer, Abdominal pain, Safety, Immunohistochemistry, Fatigue, ADC, Daiichi Sankyo, Food, IHC, Sepsis, NSCLC, Appetite, Biliary tract, Constipation, NCCN, MD, Priority review, Fatality, Pneumonitis, HER2, ILD, Medication, Pneumonia, AstraZeneca, COVID-19, Biomarker, Diarrhea, Bleeding, MD Anderson Cancer Center, Nausea, Upper respiratory tract infection, Pharmaceutical industry

The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .

Key Points: 
  • The first tumor agnostic approval of a HER2 directed therapy and ADC was based on efficacy data in 192 adult patients with previously treated unresectable or metastatic HER2 positive (IHC 3+) solid tumors who were enrolled in one of three multicenter phase 2 trials from the DESTINY clinical development program, including DESTINY-PanTumor02 , DESTINY-Lung01 or DESTINY-CRC02 .
  • In DESTINY-PanTumor02, efficacy was assessed in a subgroup of previously treated patients (n=111) with centrally or locally assessed HER2 positive (IHC 3+) solid tumors including either biliary tract, bladder, cervical, endometrial, ovarian, pancreatic or other tumors.
  • In DESTINY-Lung01, efficacy was assessed in a subgroup of patients (n=17) with centrally confirmed HER2 positive (IHC 3+) non-small cell lung cancer (NSCLC).
  • In DESTINY-CRC02, efficacy was assessed in the subgroup of patients (n=64) with centrally confirmed HER2 positive (IHC 3+) colorectal cancer.

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Retrieved on: 
Donnerstag, April 4, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sentinel lymph node, SCC, Congress, Castle, Risk, Patient, Neoplasm, Research, NCCN, AJCC, National Comprehensive Cancer Network, Risk assessment, Lymph node, Carcinoma, Melanoma, Trial of the century, Recurrence, Metastasis, SLN, Medical imaging

Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.

Key Points: 
  • Summary: The DecisionDx-Melanoma test has been validated to predict individual risk of SLNB positivity and five-year risk of recurrence and metastasis for patients with CM.
  • This study explored the cost-savings impact of using the DecisionDx-Melanoma test to guide risk-aligned clinical decision-making versus using the current melanoma staging standard, a patient’s AJCC stage.
  • Summary: The DecisionDx-SCC test uses a patient’s tumor biology to independently predict risk of regional or distant metastasis in patients with high-risk SCC.
  • These data demonstrate that DecisionDx-SCC improves the accuracy of risk assessment based solely on clinicopathological risk factors, leading to more appropriate risk-aligned management plans for patients with high-risk SCC.